Technical Data
| Formula | C9H11FN2O5 |
||||||
| Molecular Weight | 246.19 | CAS No. | 3094-09-5 | ||||
| Solubility (25°C)* | In vitro | DMSO | 49 mg/mL (199.03 mM) | ||||
| Water | 49 mg/mL (199.03 mM) | ||||||
| Ethanol | Insoluble | ||||||
| In Vivo (Add solvents to the product individually and in order.) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
|||||||
Preparing Stock Solutions
Biological Activity
| Description | Doxifluridine (5'-DFUR, AMC 0101) is an oral prodrug that is converted to the cytotoxic agent 5-fluorouracil (5-FU). |
|---|---|
| In vitro | Doxifluridine suppresses tube formation of HUVEC and vascular endothelial growth factor production by FU-MMT-1 cells. This compound is converted to 5-FU and subsequently to FdUMP, and the results suggest that it exerts its cytotoxic effects through inhibition of TS and incorporation into RNA. It is a fluoropyrimidine derivative that is activated preferentially in malignant cells by thymidine Phosphorylase to form 5-fluorouracil (5-FU). This chemical is developed to improve the therapeutic index of 5-FU and to reduce toxicity, including the immunosuppressive, myelosuppressive, and cardiotoxic effects of 5-FU and other fluorinated pyrimidines. |
| In Vivo | Metronomic Doxifluridine alone significantly suppresses tumour growth compared with the untreated (control) group, while metronomic this compound in combination with TNP-470 significantly inhibits tumour growth compared with each treatment alone in in FU-MMT-1 xenografts. This compound in combination with TNP-470 also leads to a significant reduction of intratumoural vascularity. It significantly inhibits the growth of KPL-4 tumours, reduces the tissue levels of IL-6, and alleviates body weight loss in nude mice bearing KPL-4 tumours. This chemical results in a significant reduction in the activity of phenytoin p-hydroxylation in rats. It decreases the elimination rate constant and the total clearance in rats. |
Protocol (from reference)
References
|
Sellecks Doxifluridine Has Been Cited by 4 Publications
| Development of an Extracellular Matrix Plate for Drug Screening Using Patient-Derived Tumor Organoids [ BIOCHIP J, 2023, 17, 284–292] | PubMed: None |
| Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin-proteasome pathway [ Acta Histochem, 2022, 124(4):151895] | PubMed: 35486967 |
| Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity [Lin KH, et al. Cell Metab, 2019, 29(5):1217-1231] | PubMed: 30773463 |
| Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer [Chakrabarti J Oncotarget, 2018, Oncotarget] | PubMed: 30647844 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.